Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JZP898 in advanced or metastatic solid tumors
NCT06108050Phase 1Recruiting
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2023
- Primary completion
- Nov 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of JZP898 in solid tumor (advanced stage) and metastatic solid tumor (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Dose Limiting Toxicities at 36 months, Treatment-Emergent Adverse Events at 36 months and 2 more. Started Nov 2023; status: recruiting.
02
Drugs
JZP898
03
Conditions
solid tumor (advanced stage)metastatic solid tumor
Beyond the preview
Go deeper on NCT06108050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06108050.